Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Assessment of Customized 3D Zirconium Versus Titanium Mesh for Anterior Maxillary Ridge Augmentation With Delayed Implant Placement

NCT06933030 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2024-09-01
Last updated
2025-04-17

Condition(s) studied

Ridge Augmentaton and Dental ImplantsBone Loss, Alveolar

Investigational drug(s) / intervention(s)

titanium mesh with bone graft with delayed implant placement.zirconium mesh with bone graft with delayed implant placement.

titanium mesh with bone graft with delayed implant placement.: titanium mesh with bone graft with delayed implant placement.

zirconium mesh with bone graft with delayed implant placement.: zirconium mesh with bone graft with delayed implant placement.

Study summary

The aim of the present study is to assess the customized 3D zirconium versus titanium mesh for anterior maxillary ridge augmentation with delayed implant placement.

Eligibility

Sex
ALL
Min age
20 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Inclusion criteria: 1. Patients from both genders with the age range of 18-60 years with good systemic health, no contraindication for periodontal surgery and able to maintain good oral hygiene. 2. Patient with anterior maxillary alveolar ridge deficiency (horizontal, vertical or combined defects) less than 2 mm in width or less than 6 mm in height - measured from the alveolar crest to the basal bone in order to be enrolled in this study. (56) 3. Adequate zone of keratinized gingiva at minimum 3mms. 4. Patient with sufficient inter-arch space for future dental rehabilitation. 5. Subjects who are not on any medication known to interfere with periodontal tissue health or healing within 6 months of the study. Exclusion Criteria: Exclusion Criteria: 1. History of systemic diseases (i.e. diabetes, autoimmune dysfunction, prolonged cortisone therapy, or chemotherapy) that would contraindicate periodontal surgical treatment or affect bone turn over. 2. Patients with deleterious habits like the use of tobacco chewing or smoking ones. 3. History of previous periodontal surgical treatment of the involved sites. 4. Presence of malocclusion and pathologic movement of teeth in involved sites. 5. Patient not willing to give consent for the study and poor plaque control.(57) 6. Pregnant or nursing mothers. 7. Patients with acute odontogenic infection.

Primary outcome measure(s)

  • clinical evaluation — 6 months
    The patients will be followed up clinically postoperatively every 48-72 hours for the first week then after 2weeks then one month and then after 3 months then after 6 months for preserving: Presence/absence of mesh instability, flap dehiscence, exposed mesh, bone graft loss outside the flap, hematoma or laceration.

Trial sites (1)

FacilityCityRegionStatus
Tanta university Tanta Egypt
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06933030 on ClinicalTrials.gov ↗ ← All trials in Egypt